Novel [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine and [1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine Derivatives: Synthesis, Anti-Viral In Vitro Study and Target Validation Activity
, Maxim A. Gureev 4, Aleksandra M. Puzyk 5 and Vladimir A. Ostrovskii 2,6,*Round 1
Reviewer 1 Report
Line 19, 59, 141, 14, 591, 598 – change ”3-phenyl-2-propinal” to ”3-phenyl-2-propynal”. Best check for this throughout the paper as I may have missed some.
Line 95 – change “azoenine” to “azaenyne”
Caption to Scheme 4 – change H2O to H2O
Caption to Scheme 6 - change AcN to ACN (Ac means MeC=O)
Line 142 – change “Tret-butylamine” to “tert-Butylamine”
Table 1, row “Radiation” – align first column entry with others
Line 196 – change “were the most prospective” to “was the most promising”
Line 295 – change 4a-c to 4d
Line 298 – change “ethe” to “ether”
Line 514 – change “de posed” to “deposited”
References – need to add full stop (.) at the end of each abbreviated word in journal abbreviations, for example Bioorg. Med. Chem. ; Acta Crystallogr. A
Supplementary Materials
Page 2 – the plural of “spectrum” is “spectra” so change “spectrums” to “spectra” (twice)
Otherwise all spectra are of good quality
Author Response
The authors are grateful to the reviewer for a careful and scrupulous analysis of the manuscript.
Point 1: Line 19, 59, 141, 14, 591, 598 – change ”3-phenyl-2-propinal” to ”3-phenyl-2-propynal”. Best check for this throughout the paper as I may have missed some."
Response 1: We have changed all incorrect names of the compound.
Point 2: Line 95 – change “azoenine” to “azaenyne”.
Response 2: We have changed incorrect name of the compound.
Point 3: Caption to Scheme 4 – change H2O to H2O.
Response 3: It has been corrected.
Point 4: Caption to Scheme 6 - change AcN to ACN (Ac means MeC=O).
Response 4: It has been corrected.
Point 5: Line 142 – change “Tret-butylamine” to “tert-Butylamine.
Response 5: It has been corrected.
Point 6: Table 1, row “Radiation” – align first column entry with others".
Response 6: The table has been corrected. Also added horizontal lines.
Point 7: Line 196 – change “were the most prospective” to “was the most promising”.
Response 7: It has been corrected.
Point 8: Line 295 – change 4a-c to 4d.
Response 8: It has been corrected.
Point 9: Line 298 – change “ethe” to “ether”.
Response 9: It has been corrected.
Point 10: Line 514 – change “de posed” to “deposited”.
Response 10: It has been corrected.
Point 11: References – need to add full stop (.) at the end of each abbreviated word in journal abbreviations, for example Bioorg. Med. Chem. ; Acta Crystallogr. A.
Response 11: It has been corrected.
Point 12: Page 2 – the plural of “spectrum” is “spectra” so change “spectrums” to “spectra” (twice).
Response 12: It has been corrected.
Reviewer 2 Report
Khramchikhin et al. presented a solid manuscript introducing the synthesis, in vitro anti-viral evaluation, and in silico molecular docking and modeling of novel [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine and [1,2,4]tria-2 zolo[3,4-b][1,3,4]thiadiazepine derivatives. The results are overall sound and the related discussions of their results are thorough. The narrative flows well and the English usage is professional. I would recommend this manuscript be published in Molecules, after considering the following comments and suggestions:
(1) Figure 2,3 are not very informative. The type or name of these target compounds needs to be described in either the figure caption, or a figure legend, or in the main text, to provide readers with more information about these target compounds.
(2) Line 52-64: I would recommend including a Figure to overview the current synthetic routes and the proposed synthetic routes in this manuscript.
(3) Line 108: “using 50% aqueous potassium hydroxide solution as a catalyst” reads confusing. I assume the amount of KOH added is not large (a few drops), but it reads like the reaction solvent is a 50:50 organic:aqueous cosolvent.
(4) Table 2: please provide an explanation in the main text of the table caption why CC50 and IC50 were not tested for some of these compounds. Besides, it would be nice to include negative/vehicle control
(5) Section 3.2: it is recommended to separate the compound’s full name from its nickname (for example, 1d)
Author Response
The authors are grateful to the reviewer for a thoughtful and scrupulous analysis of the manuscript.
Point 1: Figure 2,3 are not very informative. The type or name of these target compounds needs to be described in either the figure caption, or a figure legend, or in the main text, to provide readers with more information about these target compounds.
Response 1: The names of these compounds have been added to the figure legends.
Point 2: Line 52-64: I would recommend including a Figure to overview the current synthetic routes and the proposed synthetic routes in this manuscript.
Response 2: The figures have been added.
Point 3: Line 108: “using 50% aqueous potassium hydroxide solution as a catalyst” reads confusing. I assume the amount of KOH added is not large (a few drops), but it reads like the reaction solvent is a 50:50 organic:aqueous cosolvent.
Response 3: It has been corrected as: “using two drops of 50% aqueous potassium hydroxide solution as a catalyst”.
Point 4: Table 2: please provide an explanation in the main text of the table caption why CC50 and IC50 were not tested for some of these compounds. Besides, it would be nice to include negative/vehicle control.
Response 4: Currently, together with biologists, we are discussing the possibility of patenting some of the structures presented in the article, therefore we have to limit the publication of some of the obtained data on biological activity.
Point 5: Section 3.2: it is recommended to separate the compound’s full name from its nickname (for example, 1d).
Response 5: The full names of the compounds have been separated from their nicknames by parentheses in the titles of the experiments.
